SCHEMBL2653986

SCHEMBL2653986

O=C(O)CCNC(=O)c1ccc(N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)Oc2ccc3oc4ccccc4c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 13/20 0.44
GIPR P48546 10/20 0.44
GLP1R P43220 2/20 0.44
MAPK14 Q16539 2/20 0.40
SERPINE1 P05121 1/20 0.39
LMNA P02545 2/20 0.39
HDAC6 Q9UBN7 2/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
ADCY6 O43306 1/20 0.37
ADCY3 O60266 1/20 0.37
ADCY9 O60503 1/20 0.37
ADCY5 O95622 1/20 0.37
ADCY8 P40145 1/20 0.37
ADCY7 P51828 1/20 0.37
ADCY2 Q08462 1/20 0.37
ADCY1 Q08828 1/20 0.37
ADCY4 Q8NFM4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653269 0.92 GCGR (0.38) GCGRGIPRGLP1RMAPK14SERPINE1
SCHEMBL6758434 0.89 GCGR (0.55) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL2655182 0.87 MAPK14 (0.48) GCGRGIPRGLP1RMAPK14ADCY6
SCHEMBL2655483 0.86 GCGR (0.42) GCGRGIPRGLP1RLMNAHDAC6
SCHEMBL2659232 0.85 SERPINE1 (0.50) GCGRGIPRGLP1RMAPK14SERPINE1
SCHEMBL6753281 0.82 GCGR (0.53) GCGRGIPRGLP1RMAPK14SERPINE1
SCHEMBL2654369 0.81 GCGR (0.46) GCGRGIPRGLP1RADCY6ADCY3
SCHEMBL2659710 0.80 MAPK14 (0.43) GCGRGIPRGLP1RMAPK14ADCY6
SCHEMBL4087506 0.78 GCGR (0.62) GCGRGIPRGLP1RHDAC6HDAC11
SCHEMBL2654511 0.74 GCGR (0.62) GCGRGIPRGLP1RMAPK14ADCY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152750-A1 Novel glucagon antagonists NOVO NORDISK A/S (DK) 2004-08-05 US disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152750-A1 Novel glucagon antagonists GLP1R, GCGR, GIPR GCGR 2/4885GIPR 3/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.